Prognostic Significance of Pretreatment 18F-FDG PET/CT in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Treated by Radioimmunotherapy Using 131I-Rituximab

Publisher： Karger

E-ISSN： 1421-9662|130|2|74-82

ISSN： 0001-5792

Source： Acta Haematologica, Vol.130, Iss.2, 2013-03, pp. : 74-82

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The role of bone marrow biopsy and FDG‐PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non‐Hodgkin B‐cell lymphoma and Hodgkin lymphoma. accuracy in a multicenter series of 372 patients

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 8, 2015-08 ,pp. : 686-690

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab in Combination with Interferon-Alpha in Relapsed and Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma

By  

Acta Haematologica, Vol. 106, Iss. 3, 2001-11 ,pp. : 141-142

Karger

Access to resources Recommend Favorite

Risk stratification in patients with advanced‐stage breast cancer by pretreatment [18F]FDG PET/CT

By  

CANCER, Vol. 121, Iss. 22, 2015-11 ,pp. : 3965-3974

John Wiley & Sons Inc

Access to resources Recommend Favorite

Predictive Value of F-18 FDG PET/CT for Malignant Pleural Effusion in Non-Small Cell Lung Cancer Patients

By  

Oncology Research and Treatment, Vol. 34, Iss. 6, 2011-05 ,pp. : 298-303

Karger

Access to resources Recommend Favorite

The combination of milatuzumab, a humanized anti‐CD74 antibody, and veltuzumab, a humanized anti‐CD20 antibody, demonstrates activity in patients with relapsed and refractory B‐cell non‐Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 701-710

John Wiley & Sons Inc

Access to resources Recommend Favorite